DGX Quest Diagnostics Incorporated Common Stock
$240,04
Cena · Sie 19, 2026
Dane fundamentalne na dzień Lip 23, 2026
Zakres 52 tyg.
$171–$242
97% of range
Ocena Analityków
HOLD
23 analysts
Cena Docelowa
$246
+2% upside
P/E (TTM)
27.7
ROE
14.2%
Marża Zysku Netto
9.0%
O Quest Diagnostics Incorporated Common Stock Przegląd firmy z Wikipedii
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Czytaj więcej
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
DGX Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$240.04
Kapitalizacja Rynkowa
$26.64B
P/E (TTM)
27.7
EPS (TTM)
$8.75
Przychody (TTM)
$11.04B
Stopa dywidendy
1.3%
ROE
14.2%
D/E Dług/Kapitał
0.8
Zakres 52 tyg.
$171 – $242
DGX Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$11.04B
2016-12-31
→
2025-12-31
EPS
$8.75
2016-12-31
→
2025-12-31
Wolny przepływ pieniężny
$1.36B
2016-12-31
→
2025-12-31
Marże
9.0%
2016-12-31
→
2020-12-31
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
DGX
Mediana porównawcza
P/E (TTM)
27.7
26.5
P/S (TTM)
2.4
2.0
P/B
3.7
4.9
EV / EBITDA
15.0
—
Price / FCF (Cena / FCF)
19.6
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
DGX
Mediana porównawcza
Operating Margin (Marża Operacyjna)
14.1%
—
Net Profit Margin (Marża Zysku Netto)
9.0%
4.0%
ROA
6.1%
5.0%
ROE
14.2%
15.2%
ROIC
9.2%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
DGX
Mediana porównawcza
Debt / Equity (Dług / Kapitał Własny)
0.8
—
Current Ratio (Wskaźnik bieżący)
1.0
1.6
Quick Ratio (Wskaźnik Szybkości)
0.8
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
DGX
Mediana porównawcza
Revenue YoY (Przychody R/R)
11.8%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
3.7%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
3.2%
—
EPS YoY
13.8%
—
Net Income YoY (Zysk Netto R/R)
13.9%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
DGX
Mediana porównawcza
Payout Ratio (Wskaźnik Wypłaty Dywidendy)
35.6%
—
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
Stopa Dywidendy
1.3%
Wskaźnik Wypłaty Dywidendy
35.6%
CAGR dywidendy 5-letni
—
| Data ex-dywidendy | Kwota |
|---|---|
| 8 lipca 2026 | $0,8600 |
| 6 kwietnia 2026 | $0,8600 |
| 13 stycznia 2026 | $0,8000 |
| 3 października 2025 | $0,8000 |
| 7 lipca 2025 | $0,8000 |
| 7 kwietnia 2025 | $0,8000 |
| 14 stycznia 2025 | $0,7500 |
| 4 października 2024 | $0,7500 |
| 8 lipca 2024 | $0,7500 |
| 5 kwietnia 2024 | $0,7500 |
| 16 stycznia 2024 | $0,7100 |
| 5 października 2023 | $0,7100 |
| 10 lipca 2023 | $0,7100 |
| 6 kwietnia 2023 | $0,7100 |
| 17 stycznia 2023 | $0,6600 |
| 3 października 2022 | $0,6600 |
| 5 lipca 2022 | $0,6600 |
| 5 kwietnia 2022 | $0,6600 |
| 18 stycznia 2022 | $0,6200 |
| 4 października 2021 | $0,6200 |
DGX Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
23 analityków
- Mocne kupno 6 26,1%
- Kup 7 30,4%
- Trzymaj 10 43,5%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
15 analityków · 2026-08-16
Mediana
$250.00
Teraz
$240.04
Niski
$204.00
Wysoki
$265.00
Średni cel
$250.00
+4,1%
Średnia cel
$245.87
+2,4%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.09%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $3.12 | $2.85 | 0.27% |
| 31 marca 2026 | $2.50 | $2.37 | 0.13% |
| 31 grudnia 2025 | $2.42 | $2.38 | 0.04% |
| 30 września 2025 | $2.60 | $2.53 | 0.07% |
| 30 czerwca 2025 | $2.62 | $2.60 | 0.02% |
| 31 marca 2025 | $2.21 | $2.17 | 0.04% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | — |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | — |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | — |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| CHE | — | 23.3 | 4.1% | 10.5% | 24.4% | — |
| HIMS | — | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
Bilans 27
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
Przepływy pieniężne 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
Rentowność 8
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
Płynność i wypłacalność 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
Stopy Wzrostu 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
Rachunek zysków i strat 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | -223,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | -236,000,000 | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | -226,000,000 | 113,000,000 | 113,000,000 | 113,000,000 | -224,000,000 | 113,000,000 | 112,000,000 | 112,000,000 | -228,000,000 | 114,000,000 | 114,000,000 | 113,000,000 | -240,000,000 | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
Bilans 26
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
Przepływy pieniężne 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
Płynność i wypłacalność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Wycena (TTM) 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.52B | $11.12B | · | $10.72B | $10.30B | $9.90B | · | $9.55B | $9.40B | $9.33B | · | $9.45B | $9.61B | $9.88B | · | $10.32B | |
| Net Income TTM | $1.10B | $999M | · | $973M | $957M | $869M | · | $874M | $883M | $856M | · | $918M | $927M | $1.05B | · | $1.35B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 21.8 | 22.2 | · | 22.3 | 21.3 | 22.0 | · | 20.2 | 17.6 | 17.7 | · | 15.3 | 17.7 | 16.0 | · | 11.1 | |
| P/S | 2.0 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.4 | 1.6 | 1.6 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| P / FCF | · | 132.6 | · | · | · | 96.2 | · | · | · | 295.5 | · | · | · | -480.2 | · | · | |
| EV / EBITDA | 46.8 | 40.0 | · | 40.2 | 34.9 | 38.6 | · | 50.3 | 32.9 | 36.6 | · | 30.5 | 35.1 | 38.0 | · | 26.6 | |
| EV / FCF | · | 133.3 | · | · | · | 95.2 | · | · | · | 304.1 | · | · | · | -474.9 | · | · | |
| EV / Revenue | 2.5 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Earnings Yield | 4.6% | 4.5% | · | 4.5% | 4.7% | 4.5% | · | 5.0% | 5.7% | 5.6% | · | 6.5% | 5.7% | 6.2% | · | 9.0% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Marża Operacyjna % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Zysk netto | $992M | $871M | $854M | $946M | $2.00B |
| Rozwodniony EPS | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| Wskaźnik bieżący | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| Wskaźnik Szybkości | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $1.36B | $909M | $864M | $1.31B | $1.83B |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 1 181 emitentów · $12.9B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 121 (-13 vs poprzedni kw.) | 63 (-19 vs poprzedni kw.) | 408 (+62 vs poprzedni kw.) | 330 (-21 vs poprzedni kw.) | +21.9M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1 533 117 858 | 7 233 394 | 11,92% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 299 474 988 | 6 131 045 | 10,10% | Akcje |
| STATE STREET CORP | $1 169 252 484 | 5 516 643 | 9,09% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $584 135 885 | 2 767 754 | 4,54% | Akcje |
| EdgePoint Investment Group Inc. | $476 372 038 | 2 247 568 | 3,70% | Akcje |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400 206 122 | 1 888 207 | 3,11% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $357 050 202 | 1 684 597 | 2,78% | Akcje |
| Davis Selected Advisers | $329 781 509 | 1 555 612 | 2,56% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $311 037 928 | 1 467 506 | 2,42% | Akcje |
| NORGES BANK | $298 133 109 | 1 406 620 | 2,32% | Akcje |
| FMR LLC | $227 315 614 | 1 072 496 | 1,77% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $173 422 135 | 818 220 | 1,35% | Akcje |
| M&G PLC | $168 677 800 | 795 650 | 1,31% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $131 756 386 | 621 639 | 1,02% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $122 662 706 | 625 894 | 0,95% | Akcje |
| AMERIPRISE FINANCIAL INC | $109 652 758 | 517 352 | 0,85% | Akcje |
| Woodline Partners LP | $102 974 000 | 485 841 | 0,80% | Akcje |
| FIDUCIARY MANAGEMENT INC /WI/ | $102 489 906 | 483 557 | 0,80% | Akcje |
| Artemis Investment Management LLP | $99 175 856 | 467 921 | 0,77% | Akcje |
| CRAWFORD INVESTMENT COUNSEL INC | $97 514 204 | 460 081 | 0,76% | Akcje |
| PRINCIPAL FINANCIAL GROUP INC | $91 995 201 | 434 042 | 0,72% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $90 834 224 | 428 564 | 0,71% | Akcje |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $86 608 697 | 407 302 | 0,67% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $83 772 178 | 395 245 | 0,65% | Akcje |
| M.D. Sass, LLC | $76 397 960 | 360 453 | 0,59% | Akcje |
| Qube Research & Technologies Ltd | $72 783 206 | 343 398 | 0,57% | Akcje |
| MACKENZIE FINANCIAL CORP | $70 641 875 | 333 295 | 0,55% | Akcje |
| Advisors Capital Management, LLC | $69 429 626 | 327 575 | 0,54% | Akcje |
| Swiss National Bank | $65 683 305 | 309 900 | 0,51% | Akcje |
| Balyasny Asset Management L.P. | $58 364 883 | 275 371 | 0,45% | Akcje |
| Mitsubishi UFJ Asset Management Co., Ltd. | $56 877 630 | 268 354 | 0,44% | Akcje |
| RHUMBLINE ADVISERS | $56 744 612 | 267 727 | 0,44% | Akcje |
| BlackRock, Inc. | $55 976 419 | 264 102 | 0,44% | Akcje |
| Sumitomo Mitsui Trust Group, Inc. | $54 809 634 | 258 597 | 0,43% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $53 654 295 | 253 146 | 0,42% | Akcje |
| Quantinno Capital Management LP | $53 607 358 | 252 924 | 0,42% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $53 249 860 | 251 238 | 0,41% | Akcje |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $52 211 551 | 246 339 | 0,41% | Akcje |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $51 484 139 | 242 907 | 0,40% | Akcje |
| Clark Capital Management Group, Inc. | $51 259 362 | 241 846 | 0,40% | Akcje |
| Vanguard Global Advisers, LLC | $51 025 267 | 240 742 | 0,40% | Akcje |
| Legal & General Group Plc | $50 185 731 | 236 781 | 0,39% | Akcje |
| FIL Ltd | $49 419 958 | 233 168 | 0,38% | Akcje |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $49 341 000 | 232 797 | 0,38% | Akcje |
| Eurizon Capital SGR S.p.A. | $47 173 414 | 222 564 | 0,37% | Akcje |
| BARCLAYS PLC | $45 003 978 | 212 333 | 0,35% | Akcje |
| PFA Pension, Forsikringsaktieselskab | $43 579 660 | 205 613 | 0,34% | Akcje |
| Integral Health Asset Management, LLC | $42 390 000 | 200 000 | 0,33% | Akcje |
| California Public Employees Retirement System | $41 574 204 | 196 151 | 0,32% | Akcje |
| CONNING INC. | $39 578 271 | 186 734 | 0,31% | Akcje |
| SEB Asset Management AB | $38 766 863 | 182 906 | 0,30% | Akcje |
| BANK OF MONTREAL /CAN/ | $38 512 587 | 181 706 | 0,30% | Akcje |
| GOLDMAN SACHS GROUP INC | $38 322 295 | 180 808 | 0,30% | Akcje |
| Boston Partners | $35 509 632 | 167 514 | 0,28% | Akcje |
| Focus Partners Wealth | $34 616 947 | 163 327 | 0,27% | Akcje |
| STOREBRAND ASSET MANAGEMENT AS | $34 117 592 | 160 970 | 0,27% | Akcje |
| COOKSON PEIRCE & CO INC | $32 977 089 | 155 589 | 0,26% | Akcje |
| UBS Group AG | $32 934 699 | 155 389 | 0,26% | Akcje |
| BRAUN STACEY ASSOCIATES INC | $32 724 232 | 154 396 | 0,25% | Akcje |
| Willis Investment Counsel | $32 110 425 | 151 500 | 0,25% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $31 795 403 | 162 238 | 0,25% | Akcje |
| LPL Financial LLC | $30 325 576 | 143 079 | 0,24% | Akcje |
| APG Asset Management N.V. | $27 869 580 | 150 334 | 0,22% | Akcje |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $26 893 912 | 126 888 | 0,21% | Akcje |
| &PARTNERS | $26 382 365 | 124 363 | 0,21% | Akcje |
| JANE STREET GROUP, LLC | $25 942 680 | 122 400 | 0,20% | Opcja kupna |
| BANK OF AMERICA CORP /DE/ | $25 492 499 | 120 276 | 0,20% | Akcje |
| Candriam S.C.A. | $25 459 925 | 120 238 | 0,20% | Akcje |
| Squarepoint Ops LLC | $24 974 280 | 117 831 | 0,19% | Akcje |
| Gotham Asset Management, LLC | $24 911 119 | 117 533 | 0,19% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24 607 896 | 116 373 | 0,19% | Akcje |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $24 569 456 | 115 921 | 0,19% | Akcje |
| Robeco Institutional Asset Management B.V. | $23 854 123 | 112 546 | 0,19% | Akcje |
| AEGON ASSET MANAGEMENT UK Plc | $22 866 862 | 107 888 | 0,18% | Akcje |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $22 670 926 | 106 964 | 0,18% | Akcje |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22 530 921 | 106 303 | 0,18% | Akcje |
| MERCER GLOBAL ADVISORS INC /ADV | $22 064 117 | 104 101 | 0,17% | Akcje |
| Moran Wealth Management, LLC | $22 053 609 | 104 051 | 0,17% | Akcje |
| ABN AMRO Bank N.V. | $21 523 733 | 101 667 | 0,17% | Akcje |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $21 496 202 | 123 876 | 0,17% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21 322 170 | 100 600 | 0,17% | Opcja kupna |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $21 146 252 | 99 770 | 0,16% | Akcje |
| AVIVA PLC | $20 378 569 | 96 148 | 0,16% | Akcje |
| SCHWARTZ INVESTMENT COUNSEL INC | $20 326 005 | 95 900 | 0,16% | Akcje |
| Boston Common Asset Management, LLC | $20 282 767 | 95 696 | 0,16% | Akcje |
| CAPTRUST FINANCIAL ADVISORS | $20 146 790 | 95 054 | 0,16% | Akcje |
| Midwest Trust Co | $20 113 207 | 94 896 | 0,16% | Akcje |
| LAZARD ASSET MANAGEMENT LLC | $20 035 210 | 94 528 | 0,16% | Akcje |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $19 842 759 | 93 620 | 0,15% | Akcje |
| BLAIR WILLIAM & CO/IL | $19 773 115 | 93 291 | 0,15% | Akcje |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $19 613 005 | 92 536 | 0,15% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19 160 280 | 90 400 | 0,15% | Opcja sprzedaży |
| CITADEL ADVISORS LLC | $18 821 160 | 88 800 | 0,15% | Opcja kupna |
| WELLINGTON MANAGEMENT GROUP LLP | $17 507 282 | 82 601 | 0,14% | Akcje |
| Foundry Partners, LLC | $17 338 432 | 102 473 | 0,13% | Akcje |
| MARSHALL WACE, LLP | $17 187 874 | 81 094 | 0,13% | Akcje |
| Coho Partners, Ltd. | $16 981 317 | 89 103 | 0,13% | Akcje |
| Copeland Capital Management, LLC | $16 902 800 | 79 749 | 0,13% | Akcje |
| CIBC Asset Management Inc | $16 674 318 | 78 671 | 0,13% | Akcje |
| Mitsubishi UFJ Trust & Banking Corp | $16 558 594 | 78 125 | 0,13% | Akcje |
Insiderzy spółki 53 insiderów · 26 dyrektorzy generalni · 26 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 1 czerwca 2026 S | 132 423 | 0 | 5 | $-14 656 302 |
| Surya N Mohapatra | Chairman, President & CEO | 30 kwietnia 2012 F | 243 713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 22 lipca 2026 A | 33 478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 7 marca 2022 F | 98 981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 5 marca 2013 F | 126 722 | 0 | 0 | $0 |
| Mark E Delaney | SVP & Chief Commercial Officer | 28 lipca 2026 S | 10 335 | 0 | 1 | $-376 288 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22 lipca 2026 L | 13 557 | 0 | 2 | $-2 167 772 |
| Patrick Plewman | SVP for Diagnostic Services | 22 lipca 2026 L | 15 293 | 0 | 5 | $-3 023 678 |
| Catherine T. Doherty | EVP, Regional Businesses | 5 marca 2026 S | 67 122 | 0 | 7 | $-6 671 228 |
| Michael E Prevoznik | SVP & General Counsel | 5 marca 2026 S | 37 557 | 0 | 7 | $-6 505 199 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 4 marca 2026 F | 35 196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 24 września 2024 F | 4 673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 7 marca 2022 F | 48 391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 17 lutego 2021 A | 29 045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 1 marca 2019 F | 6 261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 8 marca 2018 M | 31 757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 1 marca 2018 G | 37 760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 2 marca 2015 F | 11 837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 13 lutego 2014 A | 19 890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 31 marca 2013 F | 9 569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 29 lutego 2012 F | 89 232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 16 czerwca 2011 M | 47 150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 12 lutego 2007 A | 12 974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 12 lutego 2007 A | 31 079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 12 lutego 2007 A | — | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 28 lutego 2004 F | 49 609 | 0 | 0 | $0 |
| Wright Lassiter III | Dyrektor | 22 lipca 2026 L | 10 323 | 0 | 0 | $0 |
| Vicky B Gregg | Dyrektor | 22 lipca 2026 A | 18 386 | 0 | 1 | $-239 700 |
| Robert B Carter | Dyrektor | 22 lipca 2026 L | 3 864 | 0 | 0 | $0 |
| Timothy L Main | Dyrektor | 22 lipca 2026 L | 22 460 | 0 | 0 | $0 |
| Timothy C Wentworth | Dyrektor | 1 lipca 2026 A | 1 358 | 0 | 0 | $0 |
| Timothy M Ring | Dyrektor | 20 maja 2026 A | 31 140 | 0 | 0 | $0 |
| Gary M Pfeiffer | Dyrektor | 20 maja 2026 A | 31 005 | 0 | 1 | $-270 317 |
| Luis Diaz | Dyrektor | 15 maja 2025 A | 4 054 | 0 | 0 | $0 |
| Tracey Doi | Dyrektor | 15 maja 2025 A | 6 490 | 0 | 0 | $0 |
| Gail R Wilensky | Dyrektor | 17 maja 2023 A | 20 506 | 0 | 0 | $0 |
| Stephen H Rusckowski | Dyrektor | 6 marca 2023 F | 389 597 | 0 | 0 | $0 |
| Helen Torley | Dyrektor | 25 maja 2021 A | 6 260 | 0 | 0 | $0 |
| Daniel Stanzione | Dyrektor | 23 listopada 2020 S | 28 349 | 0 | 0 | $0 |
| Jenne K Britell | Dyrektor | 4 czerwca 2018 G | 14 479 | 0 | 0 | $0 |
| Jeffrey M Leiden | Dyrektor | 29 maja 2018 S | 6 000 | 0 | 0 | $0 |
| John B Ziegler | Dyrektor | 22 lutego 2017 S | 16 557 | 0 | 0 | $0 |
| John C Baldwin MD | Dyrektor | 12 sierpnia 2015 S | 12 949 | 0 | 0 | $0 |
| William F Buehler | Dyrektor | 12 lutego 2014 M | 26 225 | 0 | 0 | $0 |
| GSK plc | Dyrektor | 31 stycznia 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | Dyrektor | 6 maja 2010 A | 9 334 | 0 | 0 | $0 |
| William R Grant | Dyrektor | 1 kwietnia 2007 A | 3 334 | 0 | 0 | $0 |
| James F Flaherty III | Dyrektor | 4 maja 2006 A | 1 667 | 0 | 0 | $0 |
| Kenneth D Brody | Dyrektor | 28 kwietnia 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | Dyrektor | 1 kwietnia 2004 A | 2 627 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 13 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 18 maja 2011 | — | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| Niezgłoszona osoba raportująca | 1 lutego 2011 | — | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 20 marca 2009 | — | Pierwotne zgłoszenie | — | SEC |
| GlaxoSmithKline plc ×2 zgłoszenia | 18 września 2008 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 16 lutego 2007 | — | Pierwotne zgłoszenie | — | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 zgłoszenia | 19 stycznia 2006 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 15 grudnia 2004 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 29 czerwca 2004 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 24 czerwca 2002 | — | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| Niezgłoszona osoba raportująca | 22 maja 2002 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 12 kwietnia 2002 | — | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 zgłoszenia | 1 listopada 2001 | — | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| Niezgłoszona osoba raportująca | 14 maja 2001 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 183 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| IHF · iShares Trust | 3,91% | 203 179 SH | 8 sierpnia 2026 | Dziennie |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,77% | 58 107 SH | 8 sierpnia 2026 | Dziennie |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,29% | 57 932 NS | 30 kwietnia 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,22% | 9 813 SH | 8 sierpnia 2026 | Dziennie |
| TMFX · RBB Fund, Inc. | 1,05% | 1 724 NS | 31 maja 2026 | N-PORT |
| ANEW · ProShares Trust | 0,92% | 364 NS | 31 maja 2026 | N-PORT |
| QLTY · GMO ETF Trust | 0,85% | 196 208 NS | 31 maja 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 0,82% | 4 047 NS | 30 kwietnia 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,80% | 635 NS | 30 kwietnia 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,76% | 4 201 SH | 8 sierpnia 2026 | Dziennie |
| QLV · FlexShares Trust | 0,74% | 6 461 NS | 30 kwietnia 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 0,72% | 741 NS | 31 maja 2026 | N-PORT |
| ESMV · iShares Trust | 0,72% | 236 SH | 8 sierpnia 2026 | Dziennie |
| HUSV · First Trust Exchange-Traded Fund III | 0,52% | 1 956 NS | 30 kwietnia 2026 | N-PORT |
| ITAN · EA Series Trust | 0,46% | 2 110 NS | 29 maja 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,44% | 1 055 NS | 30 kwietnia 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,44% | 409 814 NS | 30 kwietnia 2026 | N-PORT |
| IYH · iShares Trust | 0,43% | 66 179 SH | 8 sierpnia 2026 | Dziennie |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,41% | 3 999 NS | 31 maja 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,40% | 711 079 SH | 8 sierpnia 2026 | Dziennie |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,38% | 8 682 NS | 30 kwietnia 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 8 368 NS | 30 kwietnia 2026 | N-PORT |
| IMCV · iShares Trust | 0,37% | 17 734 SH | 8 sierpnia 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,35% | 51 278 NS | 30 kwietnia 2026 | N-PORT |
| SUSA · iShares Trust | 0,35% | 60 308 SH | 8 sierpnia 2026 | Dziennie |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,34% | 23 030 NS | 30 kwietnia 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,34% | 330 273 SH | 8 sierpnia 2026 | Dziennie |
| IXJ · iShares Trust | 0,33% | 58 047 SH | 8 sierpnia 2026 | Dziennie |
| RXL · ProShares Trust | 0,31% | 1 147 NS | 31 maja 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,31% | 2 194 NS | 30 kwietnia 2026 | N-PORT |
| GNOM · Global X Funds | 0,28% | 789 NS | 31 maja 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,26% | 79 983 NS | 30 kwietnia 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,26% | 7 703 000 | 8 sierpnia 2026 | Dziennie |
| IWS · iShares Trust | 0,25% | 166 611 SH | 8 sierpnia 2026 | Dziennie |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,24% | 18 806 NS | 30 kwietnia 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 8 995 NS | 30 kwietnia 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0,23% | 3 340 NS | 30 kwietnia 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 26 229 NS | 30 kwietnia 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 4 242 SH | 8 sierpnia 2026 | Dziennie |
| VO · VANGUARD INDEX FUNDS | 0,23% | 2 398 948 SH | 8 sierpnia 2026 | Dziennie |
| BFOR · ALPS ETF Trust | 0,22% | 2 467 NS | 31 maja 2026 | N-PORT |
| EUSA · iShares, Inc. | 0,22% | 17 880 SH | 8 sierpnia 2026 | Dziennie |
| DFVE · DoubleLine ETF Trust | 0,22% | 307 NS | 31 marca 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 0,22% | 4 307 SH | 8 sierpnia 2026 | Dziennie |
| RSP · Invesco Exchange-Traded Fund Trust | 0,22% | 910 753 SH | 8 sierpnia 2026 | Dziennie |
| GSEW · Goldman Sachs ETF Trust | 0,20% | 18 310 NS | 31 maja 2026 | N-PORT |
| ACWV · iShares, Inc. | 0,20% | 28 277 SH | 8 sierpnia 2026 | Dziennie |
| DEUS · DBX ETF Trust | 0,20% | 2 734 NS | 29 maja 2026 | N-PORT |
| IWR · iShares Trust | 0,19% | 449 590 SH | 8 sierpnia 2026 | Dziennie |
| IMCB · iShares Trust | 0,18% | 12 737 SH | 8 sierpnia 2026 | Dziennie |